Lead Product(s): GFB-887
Therapeutic Area: Nephrology Product Name: GFB-887
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Eventide Asset Management
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Funding June 30, 2020
Proceeds from the Series B financing will enable the advancement of GFB-887 and GFB-024 through three potential clinical proof-of-concept readouts and will also support continued development of the Company’s discovery platform and preclinical pipeline.